Madison-based Stratatech Corp., a leader in regenerative medicine, continues to receive funding to support the clinical and manufacturing development of its skin treatment products. Most recently, Stratatech was awarded the coveted U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) contract for StrataGraft® skin tissue, the company’s skin replacement product that acts as a medical countermeasure to treat patients with severe thermal burns. The five-year contract is valued up to $47.2 million.


Stratatech is one of the first Wisconsin companies awarded the BARDA contract, which will fund manufacturing process development and scale-up for large production volumes that are needed in case of a mass casualty event, as well as for general commercial needs. The company was founded in 2000 to commercialize the discovery of NIKS® cells – a human keratinocyte cell line that produces living tissue nearly identical to native human skin – made at the University of Wisconsin-Madison.

Over the years, Stratatech has earned numerous monetary awards and funding to support the development and commercialization of its products:

  • 2009: the company was awarded a $1.7 million grant from the National Cancer Institute to develop a new product aimed at treating skin cancer
  • 2010: Stratatech earned a $3.5 million Fast-Track SBIR grant to expand the development of its anti-infective living human skin substitute
  • 2011: the company received $4.6 million from the National Institute of Diabetes and Digestive and Kidney Diseases to support the first human clinical trial of an antimicrobial skin substitute

We’re proud of the innovation and recognition that Stratatech brings to Wisconsin. For more details about Stratatech’s unique, proprietary skin substitute products, please visit: